PrimeRFP SCOUT · Federal Contract Recompete Brief

HT941026AE002BPA for pluvicto and lutathera injection — Novartis Pharmaceuticals Corp

Novartis Pharmaceuticals Corp holds $23.5M across 59 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards in the incumbent pipeline.

Defense Health Agency Hcd West
Awarding office
Novartis Pharmaceuticals Corp
Recipient
—
Estimated value
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal
Contract numberHT941026AE002
AgencyDefense Health Agency Hcd West
Awarding officeDefense Health Agency Hcd West
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentNovartis Pharmaceuticals Corp
UEING61ZA8TADW3
PSC6505

BPA FOR PLUVICTO AND LUTATHERA INJECTION is a federal award for Defense Health Agency Hcd West held by Novartis Pharmaceuticals Corp. Estimated value —.

Bonuses end Sept 30

Want the durability read on HT941026AE002? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Novartis Pharmaceuticals Corp — $23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($23.5M) · all agencies
Department of Veterans Affairs (VA)$37.6M · 160%Department of Defense (DOD)$4.7M · 20%
Open full company profile →

Related awards

Same incumbent
36C26126F0007
PLUVICTO DRUG
$4.0M
Sep 30, 2026
W81K0025FA195
LUTATHERA AND PLUVICTO
$3.2M
Sep 30, 2026
36C26126F0017
PLUVICTO FY26
$1.6M
Sep 30, 2026
36C25026N0006
PLUVICTO
$1.2M
Sep 30, 2026
36C26126F0168
PLUVICTO - LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML
$1.0M
Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract HT941026AE002?

HT941026AE002 (BPA for pluvicto and lutathera injection) is a Defense Health Agency Hcd West award with an estimated value of —, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HT941026AE002?

Defense Health Agency Hcd West awarded HT941026AE002 to Novartis Pharmaceuticals Corp.

Who is the incumbent on HT941026AE002?

Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint.

When does Novartis Pharmaceuticals Corp’s HT941026AE002 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on HT941026AE002? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HT941026AE002